Duvelisib to Combat COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

February 6, 2022

Study Completion Date

March 2, 2022

Conditions
COVID-19
Interventions
DRUG

Duvelisib

-For patients unable to administer orally, a duvelisib suspension will be administered through a nasogastric/orogastric tube.

PROCEDURE

Peripheral blood draw

"* First 10 patients enrolled~* Screening, Day 2, Day 4, Day 8, Day 10, Day 15, and Day 29"

DRUG

Placebo

-Provided by Verastem

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Verastem, Inc.

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT04372602 - Duvelisib to Combat COVID-19 | Biotech Hunter | Biotech Hunter